Tscan Therapeutics, Inc. ( (TCRX) ) has released its Q2 earnings. Here is a breakdown of the information Tscan Therapeutics, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
TScan Therapeutics, Inc. is a clinical-stage biotechnology company specializing in T cell receptor-engineered T cell therapies for cancer treatment, with a focus on hematologic malignancies and solid tumors. In its second quarter 2025 financial report, TScan Therapeutics highlighted significant advancements in its clinical programs, including the anticipated dosing of solid tumor patients with multiplex TCR-T therapies and the upcoming presentation of two-year relapse data from its ALLOHA Phase 1 trial. The company reported a substantial increase in revenue to $3.1 million, driven by its collaboration with Amgen, while research and development expenses rose to $32.6 million due to expanded manufacturing capabilities. Despite a net loss of $37 million, TScan maintains a strong cash position of $218 million, expected to fund operations into early 2027. Looking ahead, TScan aims to initiate a registrational trial for its lead candidate TSC-101 and file an IND for a new therapy, reflecting a strategic focus on advancing its pipeline and enhancing manufacturing efficiency.